Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

108.26 -0.93 (-0.85%)
Official Closing Price Updated: 7:00 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,338,588
Open 109.05
Bid (Size) 107.90 (1,000)
Ask (Size) 108.50 (200)
Prev. Close 109.19
Today's Range 107.22 - 109.31
52wk Range 73.31 - 112.90
Shares Outstanding 2,531,374,696
Dividend Yield 3.14%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗
When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation. 
Via Stocktwits

Performance

YTD
+1.7%
+1.7%
1 Month
+8.0%
+8.0%
3 Month
+27.8%
+27.8%
6 Month
+32.8%
+32.8%
1 Year
+7.2%
+7.2%

More News

Read More
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗
Via Stocktwits
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report ↗
Via Stocktwits
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Bonds
News headline image
1 Momentum Stock Worth Your Attention and 2 Facing Headwinds
Via StockStory
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
Why Revolution Medicines Stock Surged by 11% Today ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗
Via Benzinga
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
American Trade Resilience: Deficit Hits 17-Year Low as Export Surge and Tariff Shocks Reshape Global Commerce
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
Via MarketMinute
Topics Intellectual Property
News headline image
Neogen Shares Skyrocket as Q2 Earnings Beat Signals Turning Point in 3M Integration Strategy
Via MarketMinute
Topics Earnings Economy
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
Via MarketMinute
Topics Economy
News headline image
3 Drug Stocks to Buy at a Discount ↗
Via The Motley Fool
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Complete Acquisition of Cidara Therapeutics
From Merck Sharp & Dohme
Via Business Wire
News headline image
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
From Merck & Co., Inc.
Via Business Wire
News headline image
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK ↗
Via Benzinga

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 108.26
When was Merck & Co last traded?
The last trade of Merck & Co was at 01/13/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 274.05B
How many shares of Merck & Co are outstanding?
Merck & Co has 274B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.